Septerna Inc(SEPN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:33 PM ET (Korea 10/31 05:33)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.54 | Insider Own | 36.22% | Shs Outstand | 45.7M | Perf Week | 8.88% |
| Market Cap | 2.05B | Forward P/E | - | EPS next Y | -68.74% | Insider Trans | -8.53% | Shs Float | 29.8M | Perf Month | 15.64% |
| Enterprise Value | 1.70B | PEG | - | EPS next Q | -0.41 | Inst Own | 64.98% | Short Float | 11.83% | Perf Quarter | 25.79% |
| Income | -0.02B | P/S | 20.77 | EPS this Y | -22.73% | Inst Trans | 3.87% | Short Ratio | 9.05 | Perf Half Y | 86.36% |
| Sales | 0.10B | P/B | 5.2 | EPS next 5Y | - | ROA | -4.94% | Short Interest | 3.52M | Perf YTD | 57.82% |
| Book/sh | 8.47 | P/C | 5.52 | EPS past 3/5Y | -18.79% - | ROE | -6.34% | 52W High | -13.89% ($51.10) | Perf Year | 104.75% |
| Cash/sh | 7.98 | P/FCF | 19.54 | Sales past 3/5Y | - | ROIC | -5.96% | 52W Low | 150.71% ($17.55) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 74.95% | Gross Margin | 98.33% | Volatility(W/M) | 6.6% 6.31% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 17.23 | Sales Y/Y TTM | 13520.11% | Oper. Margin | -56.68% | ATR (14) | 2.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.99 | EPS Q/Q | 48.54% | Profit Margin | -24.51% | RSI (14) | 65.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.99 | Sales Q/Q | 22375.63% | SMA20 | 12% ($39.29) | Beta | 2.27 | Target Price | $54.22 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/10 | SMA50 | 12.95% ($38.96) | Rel Volume | 0.57 | Prev Close | $45.23 |
| Employees | 130 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 31.92% 39.14% | SMA200 | 37.16% ($32.08) | Avg Volume(3M) | 0.39M | Price | $44 |
| IPO | 2024/10/25 | Option/Short | Yes/Yes | Trades | 4753 | Volume | 223,464 | Change | -2.72% |
🧬 Septerna (SEPN) is a clinical-stage biotech company developing oral small-molecule drugs that target G protein-coupled receptors. Leveraging its proprietary Native Complex Platform, the company has built a broad pipeline spanning endocrinology, immune & inflammation, and metabolic diseases. Through a major collaboration with Novo Nordisk, it is also expanding into therapeutics for cardiometabolic conditions such as obesity and diabetes.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
SEPN has a sound balance sheet but weak earning power
Of every $100 in sales, $56.68 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -22.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,077. Peers typically go for $1,268.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 65.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
XPH State Street SPDR S&P Pharmaceuticals ETF <0.01% 
PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF <0.01% 
BBC Virtus Biotech Clinical Trials ETF <0.01% 
MMSC First Trust Multi-Manager Small Cap Opportunities ETF <0.01% 
DWAS Invesco Dorsey Wright SmallCap Momentum ETF <0.01% It ranks #96 of 597 in the industry
Based on market cap of $2B.
FAQ
What kind of company is SEPN?
SEPN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SEPN?
The market cap of SEPN is approximately $2.1B, ranking 2,027 within its sector.
What is the 52-week high and low for SEPN?
SEPN has recorded a 52-week high of $51.10 and a low of $17.55.
